N
TEVA icon

Natixis’s Teva Pharmaceuticals TEVA Stock Holding History

Natixis’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$964K Buy
28,444
+14,855
+109% +$495K ﹤0.01% 752
2026
Q1 		$409K Buy
13,589
+177
+1% +$5.69K ﹤0.01% 843
2025
Q4 		$419K Sell
13,412
-25,658
-66% -$632K ﹤0.01% 869
2025
Q3 		$789K Buy
39,070
+23,836
+156% +$419K ﹤0.01% 713
2025
Q2 		$255K Sell
15,234
-3,286
-18% -$53K ﹤0.01% 777
2025
Q1 		$286K Buy
+18,520
New +$331K ﹤0.01% 714
2024
Q3 		– Sell
-2,734
Closed -$44.4K – 1105
2024
Q2 		$44.4K Buy
+2,734
New +$42.1K ﹤0.01% 792
2023
Q1 		– Sell
-6,665
Closed -$60.8K – 1190
2022
Q4 		$60.8K Buy
+6,665
New +$58.2K ﹤0.01% 906
2022
Q2 		– Sell
-9,412
Closed -$88K – 1360
2022
Q1 		$88K Sell
9,412
-92,330
-91% -$771K ﹤0.01% 1125
2021
Q4 		$815K Sell
101,742
-15,097
-13% -$136K ﹤0.01% 957
2021
Q3 		$1.14M Buy
+116,839
New +$1.09M ﹤0.01% 845
2021
Q2 		– Sell
-111,393
Closed -$1.28M – 1026
2021
Q1 		$1.28M Buy
111,393
+8,999
+9% +$103K ﹤0.01% 792
2020
Q4 		$987K Sell
102,394
-12,987
-11% -$124K ﹤0.01% 805
2020
Q3 		$1.04M Sell
115,381
-296,109
-72% -$3.13M 0.01% 512
2020
Q2 		$5.07M Buy
411,490
+195,647
+91% +$2.21M 0.04% 284
2020
Q1 		$1.94M Sell
215,843
-49,378
-19% -$506K 0.02% 390
2019
Q4 		$2.58M Buy
265,221
+11,239
+4% +$100K 0.02% 512
2019
Q3 		$1.75M Buy
253,982
+18,708
+8% +$143K 0.01% 509
2019
Q2 		$2.17M Buy
235,274
+167,083
+245% +$2.01M 0.02% 432
2019
Q1 		$1.06M Sell
68,191
-519,605
-88% -$9.16M 0.01% 579
2018
Q4 		$9.06M Buy
587,796
+50,127
+9% +$1.03M 0.07% 238
2018
Q3 		$11.6M Buy
537,669
+454,546
+547% +$10.6M 0.07% 253
2018
Q2 		$2.02M Sell
83,123
-168,992
-67% -$3.45M 0.01% 518
2018
Q1 		$4.31M Buy
252,115
+205,655
+443% +$4.02M 0.03% 386
2017
Q4 		$865K Sell
46,460
-60,287
-56% -$907K 0.01% 523
2017
Q3 		$1.87M Buy
106,747
+982
+0.9% +$22.1K 0.02% 428
2017
Q2 		$3.51M Buy
105,765
+38,500
+57% +$1.19M 0.04% 272
2017
Q1 		$2.16M Buy
67,265
+15,861
+31% +$541K 0.03% 303
2016
Q4 		$1.86M Buy
51,404
+22,599
+78% +$902K 0.02% 364
2016
Q3 		$1.32M Buy
28,805
+19,393
+206% +$1.01M 0.02% 306
2016
Q2 		$473K Buy
9,412
+4,215
+81% +$224K 0.01% 331
2016
Q1 		$278K Buy
5,197
+1,988
+62% +$117K ﹤0.01% 276
2015
Q4 		$211K Buy
+3,209
New +$198K ﹤0.01% 277
2015
Q2 		– Sell
-4,332
Closed -$270K – 445
2015
Q1 		$270K Sell
4,332
-2,216
-34% -$129K ﹤0.01% 361
2014
Q4 		$377K Hold
6,548
– – 0.01% 312
2014
Q3 		$352K Buy
6,548
+1,387
+27% +$73.5K 0.01% 336
2014
Q2 		$271K Sell
5,161
-11,234
-69% -$574K ﹤0.01% 410
2014
Q1 		$866K Sell
16,395
-51,148
-76% -$2.36M 0.01% 330
2013
Q4 		$2.71M Hold
67,543
– – 0.02% 270
2013
Q3 		$2.55M Buy
67,543
+290
+0.4% +$11.3K 0.03% 274
2013
Q2 		$2.64M Buy
+67,253
New +$2.62M 0.04% 209

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Natixis's TEVA Position: Q2 2026 in Review

Natixis increased its Teva Pharmaceuticals (TEVA) stake by 109% in Q2 2026, buying an estimated $495K and bringing the position to 28,444 shares worth $964K. The position accounts for ﹤0.01% of the portfolio, ranked #752.

Natixis first reported a position in TEVA in Q2 2013 and has held it in 41 quarters since. The position peaked at $11.6M in Q3 2018. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Natixis held 28,444 shares of Teva Pharmaceuticals worth $964K as of Q2 2026.
  • Natixis bought 14,855 Teva Pharmaceuticals shares in Q2 2026, an estimated $495K.
  • Teva Pharmaceuticals made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #752 holding.
  • Natixis first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
  • Natixis's Teva Pharmaceuticals position peaked at $11.6M in Q3 2018.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.